Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
The SELECT study demonstrated that treatment with semaglutide (2.4 mg once weekly) resulted in added clinical benefit for patients with established CVD compared with placebo in the time to first end point adjudicated-confirmed major CV event (event adjudication committee [EAC]-confirmed major adverse cardiovascular event [MACE]) based on a hazard radio (HR) of 0.80 (95% confidence interval [CI], 0.72 to 0.89)
IP Valuation Insight: Keytrudas BPCIA Exposure Mercks pembrolizumab (Keytruda) is the most commercially consequential biologic facing LOE in the 2025-2030 window
It is highly water-soluble and does not need to be taken with dietary fat for absorption
Thankfully it can be replenished
US$ 26.36
US$ 25.38
US$ 29.52
US$ 23.97
US$ 21.63
